Open Targets Blog
  • Home
  • Release Notes
  • Genetics release
  • Science
  • Q&A
  • Platform
Subscribe

target identification

A collection of 23 posts

Open Targets Platform

How we improved our clinical trial curation during the COVID-19 lockdown

Learn how we leveraged the wide range of expertise amongst our lab-based experimental research colleagues to make valuable contributions to the Open Targets Platform and our target validation projects.

Ellie McDonagh
Open Targets Platform

The importance of Autophagy in drug discovery

Explore Reactome's new autophagy pathway and how it relates to drug discovery and the Open Targets Platform

Thawfeek M Varusai
Open Targets Platform

Introducing ClinGen’s Gene Validity Curations

Learn how the Open Targets Platform integrates and scores ClinGen's Gene-Disease Validity curation data to enhance rare disease associations

Asier Gonzalez, Ellie McDonagh
Open Targets Platform

Open Targets Platform 20.09 released!

We have a new release of the Open Targets Platform - 20.09 - which includes new data from ClinGen, updated Gene2Phenotype data, the removal of duplicated evidence, more clinical trial data, plus regular data updates

Andrew Hercules
coronavirus infectious disease

Open Targets releases our COVID-19 Target Prioritisation Tool

Open Targets is excited to introduce our COVID-19 Target Prioritisation Tool - http://covid19.opentargets.org/ - an interactive web portal allows users to explore host and viral targets and potential COVID-19 treatments

Andrew Hercules
release notes

Open Targets Platform 20.06 has been released!

We have a new release of the Open Targets Platform with new disease terms including COVID-19, new chemical probes, updates to Open Targets Genetics evidence and more.

Denise Carvalho-Silva
release notes

Open Targets Platform 20.04 has been released!

We have a new release of the Open Targets Platform with new target safety data, new target tractability modalities, more chemical probes and new associations.

Denise Carvalho-Silva
Q&A

Prioritising your list of potential drug targets with tractability assessments

How tractable is a drug target? In this Open Targets Q&A, we explore the ChEMBL tractability (druggability) pipeline implemented in the Open Targets Platform.

Melanie Schneider, Andrew Hercules
Open Targets Genetics

GWAS causal inference in Open Targets

Finding GWAS causal inference for target identification and prioritisation using Open Targets Genetics and the Open Targets Platform.

David Ochoa, Maya Ghoussaini
Q&A

Special Q&A with Gosia Trynka, Open Targets Experimental Science director

We're delighted to have caught up with Gosia Trynka, our new Experimental Science director, for a very special Q&A on Open Targets science and more.

Gosia Trynka, Denise Carvalho-Silva
release notes

Open Targets Platform: release 20.02 is out

We have a new release of the Open Targets Platform with a brand new data source, Open Targets Genetics Portal, more chemical probes and new intOGen data.

Denise Carvalho-Silva
Cancer

An Open Targets Away Day with The Institute of Cancer Research

Open Targets meets colleagues at the Institute of Cancer Research in London: potential collaboration ahead of us.

Ian Dunham, David Hulcoop
Q&A

Getting to know intOGen, a resource for the identification of cancer driver genes

Open Targets Q&A on identifying cancer driver genes and their mechanism of action with intOGen.

francisco Martinez-Jimenez, Denise Carvalho-Silva
ontology

EFO3: A community-driven ontology to advance clinical discoveries

In the 19.11 release of the Open Targets Platform, we moved from EFO2 to EFO3. Here we explore what the new disease ontology means to Open Targets.

David Ochoa, Denise Carvalho-Silva, Zoë May Pendlington, Paola Roncaglia
release notes

Open Targets Platform: release 19.11 is out

We have a new release of the Open Targets Platform: new EFO3, FDA pharmacovigilance data, new chemical probes, more targets, more evidence and associations.

Denise Carvalho-Silva
A-Z

From antibody to zinc finger: an A-Z of Open Targets

As scientists discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. November is time for H.

Denise Carvalho-Silva
release notes

Open Targets Platform: release 19.09 is out

We have a new release of the Open Targets Platform: more target-disease associations, more chemical probes and target enabling packages, and updated Elasticsearch.

Denise Carvalho-Silva
A-Z

From antibody to zinc finger: an A-Z of Open Targets

As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. This time we have a double bill: F and G.

Denise Carvalho-Silva
release notes

Open Targets Platform: release 19.06 is out

We have a new release of the Open Targets Platform: more target safety information and new target-disease associations are some of the highlights in release 19.06.

Denise Carvalho-Silva
release notes

Open Targets Platform: release 19.04 is out

We have a new release of the Open Targets Platform: CRISPR-Cas9 data and target safety information are some of the highlights in release 19.04.

Denise Carvalho-Silva
Q&A

Avoiding confusion in disease biology with ontologies

Open Targets Q&A on the importance of describing diseases with ontologies when searching for new therapeutic targets in drug discovery.

Zoë May Pendlington, Denise Carvalho-Silva
A-Z

From antibody to zinc finger: an A-Z of Open Targets

As users discover our freely available resources, it’s time to take a closer look at the terms that matter to Open Targets. March is time for E.

Denise Carvalho-Silva
release notes

Open Targets Platform: release 19.02 is out

Our latest release of the Open Targets Platform is out. We have more targets, more diseases, more evidence, more associations, and fixed some bugs too.

Denise Carvalho-Silva
Open Targets Blog © 2021
Latest Posts Twitter Ghost
Open Targets Blog

Subscribe to Open Targets Blog

Stay up to date! Get all the latest & greatest posts delivered straight to your inbox